Extraskeletal osteosarcoma has a favourable prognosis when treated like conventional osteosarcoma
- 348 Downloads
Purpose: The aims of this analysis were to investigate the clinical features of extraskeletal osteosarcoma (ESOS) and examine the outcome after multi-modal therapy. Methods: The co-operative osteosarcoma study-group database was searched for patients with extraskeletal osteosarcoma. Eligible patients were included in a retrospective analysis of patient, tumour and treatment related variables and outcome. As for conventional osteosarcoma, scheduled treatment included surgery and multi-agent chemotherapy. Results: Seventeen eligible patients were identified with a median age of 44 years (range, 3–65 years). The thigh was the commonest tumour site. Two patients had a history of previous malignancies and two had primary metastases. Median follow-up was 3.2 years (range: 0.6–7.4 years) and at last follow-up, 11 patients were alive in complete remission, 3 patients were alive with disease and 3 patients had died of their disease. Three-year overall actuarial and event-free survival rates were 77% and 56%, respectively. Patients with macroscopically complete surgical remission had an improved overall survival (P=0.0004). Conclusions: The patients in this retrospective study had a surprisingly good survival rate. This may be due to the combination of multi-agent chemotherapy with surgery, and we recommend this approach in the treatment of ESOS.
KeywordsExtraskeletal osteosarcoma Chemotherapy
The studies that form the basis of this work were supported by Deutsche Krebshilfe, Bundesministerium für Forschung und Technologie and Fördergemeinschaft Kinderkrebszentrum Hamburg. S.Y. Goldstein-Jackson received support from the European Community action scheme for the mobility of university students (Erasmus). The authors wish to thank all patients who contributed to the COSS studies and to acknowledge the physicians, nurses, data managers and support staff of the collaborating centres for their active participation. They would like to thank Mathias Kevric for his expert data management. The patients included in this study were from the following hospitals: Universitätsklinikum Münster, Medizinische Klinik und Poliklinik A, Germany; Kinder-Poliklinik, Päd. Onkologie/KMT, Munich; Germany; Medizinische Universitätsklinik, Abteilung Onkologie/Hämatologie, Hamburg, Germany; St. Anna Kinderspital, Vienna, Austria; Medizinische Universitätsklinik I, Cologne, Germany; Medizinische Universitätsklinik, Abteilung Onkologie/Hämatologie, Graz, Austria; Orthopädische Universitätsklinik Balgrist, Zürich, Switzerland; Katharinen – Hospital, Stuttgart; Germany; Medizinische Klinik& Poliklinik V, Heidelberg, Germany; Medizinische Universitätsklinik, Würzburg, Germany; Mutterhaus der Borromäerinnen, Trier, Germany; Medizinische Universitätsklinik I, Abt.: Hämatologie/Internistische Onkologie, Regensburg, Germany; Medizinische Klinik II mit Schwerpunkt Onkologie und Hämatologie, Charité Campus Mitte, Berlin, Germany; Universitätsklinikum Schleswig-Holstein, II. Medizinische Klinik und Poliklinik, Kiel, Germany; Kantonspital Aarau, Abteilung Pädiatrische Onkologie, Aarau, Switzerland; Diakonissenkrankenhaus, Medizinische Klinik II, Stuttgart, Germany; Medizinische Universitätsklinik, Abteilung Hämatologie/Onkologie, Rostock, Germany
- Bane BL, Evans HL, Ro JY, Carrasco CH, Grignon DJ, Benjamin RS, Ayala AG (1990) Extraskeletal Osteosarcoma: A clinicopathologic review of 26 cases. Cancer 66:2762–2770Google Scholar
- Cook PA, Murphy MS, Innis PC, Yu JS (1998) Extraskeletal osteosarcoma of the hand. J Bone Joint Surg (Am) 80:725–729Google Scholar
- Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481Google Scholar